U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07885956) titled 'A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults' on Oct. 14.

Brief Summary: This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.

Study Start Date: Oct. 29

Study Type: INTERVENTIONAL

Condition: Respiratory Syncytial Virus (RSV)

Intervention: BIOLOGICAL: RSVpreF (Regimen A)

Regimen A

BIOLOGICAL: RSVpreF (Regimen B)

Regimen B

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Pfizer

Published by HT Digital Content Services with permission from Health Daily Digest....